Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jul 24;218(5):673-675.
doi: 10.1093/infdis/jiy186.

Resistance to Dolutegravir-A Chink in the Armor?

Daniel R Kuritzkes  1
Affiliations
Editorial

Resistance to Dolutegravir-A Chink in the Armor?

Daniel R Kuritzkes. J Infect Dis. .
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

    1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV. Department of Health and Human Services; http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 25 March 2018.
    1. Günthard HF, Saag MS, Benson CA, et al. . Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the international antiviral society-USA Panel. JAMA 2016; 316:191–210. - PMC - PubMed
    1. Lennox JL, DeJesus E, Lazzarin A, et al. ; STARTMRK Investigators Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet 2009; 374:796–806. - PubMed
    1. Sax PE, DeJesus E, Mills A, et al. ; GS-US-236-0102 Study Team Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet 2012; 379:2439–48. - PubMed
    1. Lennox JL, Landovitz RJ, Ribaudo HJ, et al. ; ACTG A5257 Team Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial. Ann Intern Med 2014; 161:461–71. - PMC - PubMed